Nkarta, Inc.

Nkarta to Participate in September Investor Conferences

Nkarta announced participation in two September investor conferences: a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, and a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. Both events will be webcast simultaneously on Nkarta's investor relations website, with replays archived for approximately 90 days. No new clinical data, guidance, or business updates were disclosed in this release; it is a routine IR calendar announcement for the clinical-stage autoimmune NK cell therapy developer.

•1mo ago

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Alyssa Levin, formerly the CFO of Nkarta (NKTX), has joined Cyllene Therapeutics' Board of Directors as Chair of the Audit Committee. The release details Cyllene's strategic hires in regulatory affairs and CMC to support its lead candidate EG110A, a DNA medicine for neurogenic bladder currently in a Phase 1/2 study. These personnel changes affect Cyllene Therapeutics and have no direct operational or financial impact on Nkarta.

•3mo ago

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Nkarta President Nadir Mahmood is scheduled to participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The discussion on June 30th will focus on updates regarding the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. A live webcast of the event will be accessible on the company's website, with a replay available for 90 days.

•4mo ago

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

This press release is a paid promotional commentary issued by Equity Insider on behalf of GT Biopharma (GTBP), focusing on the natural killer (NK) cell immunotherapy sector. Compass Therapeutics (CMPX) is mentioned solely as a peer in the broader immune-engager and bispecific landscape, illustrating investor interest in scalable alternatives to cell therapy. There is no new operational, financial, or regulatory news for Compass Therapeutics; the article serves as marketing for GT Biopharma’s TriKE platform and GTB-5550 program.

•4mo ago

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

A paid commentary by Biotech Insider highlights GT Biopharma's (GTBP) clinical progress, noting that three TriKE candidates have reached human testing. The article focuses on GTB-5550, a solid-tumor NK cell engager that dosed its first patient in May 2026, and GTB-3650, a second-generation AML/MDS candidate in Phase 1. Fate Therapeutics (FATE) is mentioned briefly as a peer in the NK-cell platform space, but the release contains no new information or direct impact on FATE.

•4mo ago